July 22, 2004 — ANN ARBOR, MICH., July 22, 2004 – Velcura Therapeutics™, Inc. announced today the development of a custom Affymetrix (Nasdaq: AFFX) GeneChip® array that aids the development of bone disease therapies by enabling researchers to follow global changes in gene expression during human bone formation. Velcura worked with Affymetrix, the world leader in DNA microarray technologies, to design and produce the custom array using Affymetrix’ CustomExpress™ Array Program. This custom GeneChip array, which Velcura hopes will help speed research to help fight osteoporosis and other bone diseases, is available only to Velcura Therapeutics for use within the company for its own studies or that of its strategic partners.

July 6, 2004 — ANN ARBOR, MICH., July 6, 2004 – Michael W. Long, Ph.D., the President and CEO of Velcura Therapeutics™, Inc. announced today that two outstanding Michigan life science professionals have joined the Ann Arbor biotech company that is dedicated to fighting bone disease. "The two women who have joined our team at Velcura Therapeutics are excellent representatives of the talent available here in Michigan," said Dr. Long.

Jan. 5, 2004 — ANN ARBOR, MICH., Jan. 5, 2004 – Michael W. Long, Ph.D., the President and CEO of Velcura Therapeutics™, Inc., recently announced that Julie Glowacki, Ph.D., John Lowe, M.D. and W. Stratford May, M.D., Ph.D. have joined the biotech company’s Scientific Advisory Board (SAB).

Nov. 18, 2003 — ANN ARBOR, MICH., Nov. 18, 2003 – Daniel Chagnovich, Ph.D. has joined Velcura Therapeutics™, Inc. as senior scientist, Bioinformatics. He most recently worked at Pfizer’s Global Research and Development Center in Ann Arbor as a scientist in the Molecular Technologies group.

Oct. 6, 2003 — ANN ARBOR, MICH., Oct. 6, 2003 –Velcura Therapeutics™, Inc. recently was awarded a $224,000 Phase 1 SBIR (Small Business Innovation Research) grant from the National Institute on Aging, National Institutes of Health (NIH).